• Guanabenz Acetate in GPCR Research

  2026-09-09

  Guanabenz Acetate enables subtype-resolved α2-adrenergic receptor experiments with a practical DMSO-based workflow. This guide connects receptor pharmacology to a carefully bounded, hypothesis-driven assay strategy inspired by SARS-CoV-2 stress-granule research.

• Capsazepine Workflows for TRPV1 Research

  2026-09-09

  Capsazepine is a practical pharmacological probe for separating TRPV1-dependent calcium signaling and nociception from downstream inflammatory effects. This guide connects concentration-aware channel assays with pain-model controls, TRPM8 selectivity checks, and exploratory apoptosis sensitization studies.

• Sorafenib in Liver Cancer Research Workflows

  2026-09-08

  Build reproducible Sorafenib workflows for RAF/MEK/ERK signaling, tumor proliferation inhibition, and angiogenesis studies in liver cancer models. This guide also shows how to use Sorafenib as a mechanistic benchmark alongside mitochondrial cholesterol and mitophagy assays inspired by recent celastrol research.

• A1 and CXCR4 Inhibition in Colorectal Cancer

  2026-09-08

  Khorramdelazad et al. evaluate A1, a fluorinated CXCR4 inhibitor, through molecular dynamics, CT-26 cell experiments, and a BALB/c colorectal cancer model. A1 showed more favorable calculated CXCR4 binding than AMD3100 and produced stronger effects on tumor growth, migration, regulatory T-cell infiltration, and immunosuppressive signaling in vivo, while remaining a preclinical candidate requiring further validation.

• Guanabenz Acetate in Receptor and Stress Assays

  2026-09-07

  Guanabenz Acetate provides a subtype-aware way to perturb α2-adrenergic signaling while monitoring stress-granule and innate-immune phenotypes. This workflow connects receptor pharmacology with the GADD34–IRF3 biology reported in SARS-CoV-2 research, while clearly separating established evidence from testable assay hypotheses.

• AO/PI Staining Solution for Accurate Cell Counting

  2026-09-07

  AO/PI Staining Solution uses two fluorescent DNA dyes to distinguish cells with intact membranes from cells with compromised membranes. The K2269 reagent supports fluorescence-based cell counting and can reduce debris and red-blood-cell interference when the workflow is validated with appropriate controls.

• Phillygenin in Diabetic Nephropathy: Mechanistic Evidence

  2026-09-05

  The reference study shows that phillygenin protects against diabetic kidney injury in high-glucose podocytes and db/db mice by suppressing TLR4/MyD88/NF-κB-associated inflammation and supporting PI3K/AKT/GSK3β signaling. Its integrated use of RNA sequencing, cellular assays, biochemical readouts, histology, and animal studies provides a useful preclinical framework for connecting podocyte apoptosis with albuminuria.

• Matrine, YTHDF1, and Thymoma Stemness

  2026-09-04

  A 2026 study connects Matrine treatment with reduced stemness-associated behavior and increased apoptosis in EL-4-B5 thymoma cells, implicating YTHDF1 and Wnt/β-catenin signaling. The work offers a focused assay framework for thymoma research, while its single-model design and lack of direct m6A, in vivo, and clinical validation require cautious interpretation.

• Guanabenz Acetate in Receptor Signaling Workflows

  2026-09-04

  Guanabenz Acetate provides a practical way to resolve α2a-, α2b-, and α2c-adrenergic receptor responses in concentration-controlled GPCR assays. This guide connects receptor pharmacology with stress-granule and innate-immune readouts while clearly separating established evidence from hypothesis-generating applications.

• Capsazepine Workflows for TRPV1 Research

  2026-09-03

  Capsazepine provides a practical pharmacological switch for separating TRPV1-driven calcium signaling and nociception from TRPM8, calcium-current, and apoptosis-related effects. This workflow guide translates receptor pharmacology and a recent multimodal pain study into assay design, controls, and troubleshooting decisions.

• TaqI Restriction Endonuclease Protocol

  2026-09-03

  TaqI Restriction Endonuclease provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA containing its recognition site. It is intended for research workflows such as cloning and fragment analysis, not for diagnostic, medical, or clinical use.

• Glycogen Colorimetric Assay Kit II for Circadian Studies

  2026-09-02

  The Glycogen Colorimetric Assay Kit II enables sensitive glycogen measurement in biological samples while supporting circadian exercise research. This article connects assay chemistry with temporal sampling, normalization, and interpretation of glycogen-independent training adaptations.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-09-02

  Breen and colleagues developed a drug-sensitized Saccharomyces cerevisiae platform that markedly improves growth-based detection of TOR/mTOR inhibitors. The system detected known inhibitors at nanomolar concentrations, identified aminophylline as a TOR1-dependent growth inhibitor, and provided no evidence that several tested compounds, including nebivolol, inhibit TOR in this model.

• Multiple Myeloma Cell Lines: Mutations and Resistance

  2026-09-01

  The reference study used whole-exome sequencing across a genetically diverse panel of human multiple myeloma cell lines to define recurrent mutations, altered pathways, and genotype–drug response relationships. Its main practical contribution is a molecular framework for selecting cell-line models and interpreting resistance experiments in hematological malignancy research.

• Trilaurin: From Lipid Excipient to Smart LNP Design

  2026-09-01

  Trilaurin, also called Glycerol Tridodecanoate, is more than a hydrophobic lipid: its structure supports formulation, enzymatic synthesis, and sequential oral nanomedicine design. This article translates its chemistry into practical assay, quality-control, and platform-selection decisions.

7931 records 1/529 page Next 12345 下5页 Last page